CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Total revenues	$ 552,473	$ 778,468	$ 1,185,992	$ 1,662,791
Cost of revenues	179,582	133,141	411,613	286,626
Operating expenses:
Selling, general and administrative	2,285,544	2,528,914	4,658,957	5,611,295
Research and development	703,018	651,377	1,267,444	1,360,941
Depreciation and amortization	66,537	97,673	141,604	232,724
Total operating expenses	3,055,099	3,277,964	6,068,005	7,204,960
LOSS FROM OPERATIONS	(2,682,208)	(2,632,637)	(5,293,626)	(5,828,795)
Other (expense) income:
Interest expense (including related parties interest of $25,840 and $49,310 for the three and six months ended March 31, 2019, respectively)	(29,096)	(37,417)	(58,187)	(69,028)
Other expense, net	(239,601)	(16,703)	(261,833)	(23,254)
Loss before provision for income taxes	(2,950,905)	(2,686,757)	(5,613,646)	(5,921,077)
Provision for income taxes	0	0	0	0
NET LOSS	(2,950,905)	(2,686,757)	(5,613,646)	(5,921,077)
Less: Net (income) loss attributable to noncontrolling interest	(1,220)		(1,190)
NET LOSS attributable to Applied DNA Sciences, Inc.	(2,952,125)	(2,686,757)	(5,614,836)	(5,921,077)
Deemed dividend related to warrant modifications			(2,842)
NET LOSS applicable to common stockholders	$ (2,952,125)	$ (2,686,757)	$ (5,617,678)	$ (5,921,077)
Net loss per share applicable to common stockholders-basic and diluted	$ (0.79)	$ (3.22)	$ (1.76)	$ (6.51)
Weighted average shares outstanding-basic and diluted (in shares)	3,758,512	834,990	3,196,616	909,623
Product
Revenues:
Total revenues	$ 197,801	$ 119,036	$ 435,671	$ 440,747
Service
Revenues:
Total revenues	$ 354,672	$ 659,432	$ 750,321	$ 1,222,044